Drug profile · INN
deslanoside
CEDILANID-D
deslanoside (CEDILANID-D) is a sodium/potassium-transporting atpase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — deslanoside
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
deslanoside (CEDILANID-D) is a sodium/potassium-transporting atpase inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium/potassium-transporting ATPase inhibitor
Primary target: Sodium/potassium-transporting ATPase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is deslanoside?
deslanoside (CEDILANID-D) is a sodium/potassium-transporting atpase inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for deslanoside?
CEDILANID-D is a marketed brand name for deslanoside. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of deslanoside?
deslanoside has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.